Immunotherapy

Clinical trial results show a new antibody drug with an unconventional approach improves survival for patients with various aggressive cancers.

Targeting a key gene can help prevent the body’s immune fighters from wearing out when attacking tumour cells, offering a new treatment strategy against cancer.

Researchers find that targeting nerve growth factor in melanomas transforms resistant ‘cold’ tumours into treatable ‘hot’ ones, adding new therapeutic options for challenging skin cancers.

Researchers identify predictive immune ‘signatures’ in liver cancer patients that can help tailor and improve the success rates of combined immunotherapy and radiotherapy.

New associations between COVID-19 and immune responses in cancer patients reveal potential inroads to fighting tumours.

A T cell therapy innovation may offer new hope for acute myeloid leukemia patients who relapse after conventional treatment.

Imaging experts discover a non-invasive method to identify which patients with liver cancer are most likely to respond to immunotherapy.

A*STAR researchers discover a mechanism that fires up the metabolism of cancer-killing immune cells, paving the way for future cancer immunotherapies.

Researchers engineer specialized T cells that can transiently and effectively attack liver cancer cells even in the presence of immunosuppressive drugs.

A new biomarker in liver tumor may help doctors predict how patients respond to immunotherapy.

A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.

Just because a molecular target resides inside a cancer cell does not mean that it cannot be targeted by antibodies, says Qi Zeng, founder of A*STAR spin-off company Intra-ImmuSG.